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PART 1 
The relationship between periodontal disease and the presence 
of metabolic disorders among adults in the Atherosclerosis 
Risk in Communities (ARIC) study 
 
ROMINA PERRI, DMD  
(Under the direction of Silvana Barros, DDS, MS, PhD, James Beck, AB, MS, PhD, 
Steven Offenbacher, BA, DDS, MS, PhD) 
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THE RELATIONSHIP BETWEEN PERIODONTAL DISEASE AND THE PRESENCE 
OF METABOLIC DISORDERS AMONG ADULTS IN THE ATHEROSCLEROSIS 
RISK IN COMMUNITIES (ARIC) STUDY 
 
Abstract 
AIM: To examine the association between periodontal disease and two metabolic 
disorders (obesity, defined by Body Mass Index (BMI) and impaired fasting glucose 
(IFG)), using a cross-sectional observational study design.   
MATERIALS AND METHODS: Participants (n= 6780) who had a periodontal 
exam were selected from the Atherosclerosis Risk in Communities (ARIC) study. The 
Dental ARIC also consisted of collection of gingival crevicular fluid (GCF), oral plaque 
and serum. Level of disease was either classified by the CDC-AAP definition or Biofilm 
Gingival Interface (BGI) classification. 
RESULTS: CRP and IL-6 was statistically significant in any level of disease in 
obese patients (P <0.0001). D8Iso (P= 0.04) and sICAM-1 (P= 0.04) were significant in 
participants classified with moderate level disease (CDC-AAP) while sCD14 (P= 0.06) 
approached significance. No significant differences were observed between groups for all 
tested GCF mediators suggesting a more important systemic inflammatory component 
rather than local tissue effect. Increased odds for gingivitis (OR 1.94, 1.27-2.95) and 
BGI-P3 disease (OR 2.28, 1.49-3.50) was identified for patients that were non-obese and 
diabetic. Also, an increased likelihood for gingivitis and BGI-P3 was found in obese 
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patients that were euglycemic (OR 1.39, 1.07-1.80 and OR 1.67, 1.27-2.19, respectively) 
or had diabetes (OR 1.81, 1.24-2.64 and OR 2.31, 1.57-3.39, respectively).  
CONCLUSION: Important associations between diabetes and periodontal disease 
and obesity and periodontal disease were reaffirmed. For the first time, increased 
likelihood for gingivitis was identified in both patients with diabetes and an obese BMI. 
Reaffirmation of the critical role of CRP and IL-6 on systemic inflammatory burden was 
shown in an obese population. Prevention and management of obesity and diabetes 
should be adjunctive treatment approaches to improving overall oral health. 
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INTRODUCTION 
The prevalence of obesity, defined as a Body Mass Index (BMI) > 30.0 kg/m
2 
(Keys et al. 1972; Mora et al. 2005), has dramatically increased in children and adults 
both in the United States and throughout the world. The National Health Examination 
Survey I (NHES I) study (1960-1962) reported that the age-adjusted (18-74 years old) 
prevalence of adult obesity in the U.S. was 13.4% (Flegal et al. 2002; Ogden et al. 2006). 
In 2007-2008, the National Health
 
and Nutrition Examination Survey (NHANES) 
reported that the age-adjusted prevalence of obesity
 
nearly tripled to
 
33.8% (95% 
confidence interval [CI], 31.6%-36.0%) overall,
 
32.2% (95% CI, 29.5%-35.0%) among 
men, and 35.5% (95% CI, 33.2%-37.7%)
 
among women (Flegal et al. 2010). 
Obesity has been recognized as an important risk factor for numerous chronic 
adult diseases, including non-insulin dependent diabetes mellitus (NIDDM), 
hyperlipidemia, hypertension, arteriosclerosis and cardiovascular and cerebrovascular 
diseases (Kopelman 2000). Recently, increased interest in the link between obesity and 
oral health, has suggested that obesity is also associated with periodontitis (Perlstein and 
Bissada 1977; Saito et al. 1998, 2001, 2005; Al-Zahrani et al. 2003; Wood et al. 2003; 
Della Vecchia et al. 2005; Genco et al. 2005).  Adipose tissue secretes hormones and 
cytokines that are intimately involved in inflammatory processes suggesting that similar 
pathways may be involved in the pathophysiology of obesity, diabetes and periodontitis 
(Pischon et al. 2007) (Figure 1). If obesity is a true risk factor for periodontal disease, the 
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associations among periodontal disease, obesity and diabetes mellitus must be very 
complex because each is known to be associated with the other. 
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FIGURE 1 
 
 
Figure 1: Relationships among obesity, diabetes and periodontal disease. 
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Atherosclerosis Risk in Communities (ARIC) Study 
The ARIC study is a prospective investigation, supported by the National Heart 
Lung and Blood Institute, of the etiology and natural history of atherosclerosis and 
clinical cardiovascular disease in four US communities (Jackson, Mississippi; 
Washington County, Maryland; suburban Minneapolis, Minnesota; and Forsyth County, 
North Carolina). A sample of 15,792 community-dwelling residents aged 45 to 64 years 
at baseline took part in the evaluation of cardiovascular risk factors and their sequelae 
(The ARIC Investigators, 1989). The Dental ARIC (DARIC), a cross-sectional, ancillary 
study funded by the National Institute of Dental and Craniofacial Research, was 
conducted during ARIC Visit 4 in 1996 to 1998. The aims of the study were to determine 
the prevalence, extent and severity of periodontal conditions in the dentate ARIC 
population and to describe the associations between those conditions and prevalent 
coronary heart disease, carotid artery intima-media thickness, presence of carotid artery 
lesions, and atherosclerosis risk factors. DARIC consisted of an oral examination, 
collection of gingival crevicular fluid, oral plaque, serum and interviews (Beck et al. 
2001). 
The implications of obesity for cardiovascular disease have been well established 
with evidence from the ARIC study (Folson et al. 1991; Yatsuya et al. 2010). The 
relationship between periodontal disease and obesity in these subjects has yet to be 
investigated. The potential association of this increasingly common systemic disease 
highlights the possible benefit of identifying a modifiable risk factor related to oral health 
that may lead to overall health. 
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BACKGROUND 
Obesity and its Association to Metabolic Disorders 
An increased BMI is associated with an increase in the size and number of 
adipocytes (Mohamed-Ali et al. 1997).  Research in the field of obesity has determined 
that adipose tissue is an endocrine organ (Ahima et al. 2000) and a key participant of the 
immune system (Wellen et al. 2005).  It can secrete free fatty acids (Boden et al. 2003), 
inflammatory cytokines (Hotamisligil et al. 1996; Fain et al. 2004),
 
adipokines (leptin, 
adiponectin, resistin) (Zhang et al. 1994; Maeda et al. 1996; Kusminski et al. 2005) and 
plasminogen activator inhibitor type-1 (Shimomura et al. 1996). Reports have shown that 
production of these factors is more pronounced in obese individuals (Weisberg et al. 
2003; Bouloumié et al. 2005). Possibly due to these changes, a low-grade chronic 
systemic inflammation is observed.  
In comparison to people classified as having a normal BMI, obese people have a 
greater than 10-fold increased risk of developing NIDDM (Field et al. 2001; Pischon et 
al. 2007). Similarly, obesity has long been recognized as an important determinant of 
hypertension. Obese people have a 5 times higher risk of hypertension (Wolf et al. 1997) 
and a 1.5-fold increased risk for cardiovascular disease (Wilson et al. 2002). 
 
Periodontal Disease and Systemic Inflammation 
Periodontal disease, a chronic infection and inflammatory condition that affects 
tooth-supporting tissues, may cause local and systemic inflammatory events. Systemic 
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dissemination of the periodontopathogens or their products may induce bacteremia or 
endotoxemia, which in turn stimulates and increases levels of serum inflammatory 
markers (Wu et al. 2000). Evidence suggests that periodontal diseases can induce or 
perpetuate an elevated systemic chronic inflammatory state, as reflected in increased 
serum CRP, IL-6, and fibrinogen levels seen in many people with periodontitis (D’Aiuto 
et al. 2004; Loos et al. 2000). Nishimura and coworkers (2000) showed that serum TNF-α 
concentrations were elevated in periodontitis patients as compared to periodontally 
healthy subjects. Those periodontal patients with elevated TNF-α serum levels had 
reduced levels after periodontal therapy. In addition, two analyses using NHANES III 
data reveal that obesity measures significantly correlated with periodontal disease 
severity in adults (Della Vecchia et al. 2005; Genco et al. 2005). 
 
Association between Obesity and Periodontal Disease 
The first paper on the relationship between obesity and periodontal disease was 
published as early as 1977. An experimental ligature-induced periodontitis model was 
used in Zucker rats (Perlstein and Bissada, 1977). Greater alveolar bone resorption was 
seen in obese animals as compared with non-obese rats. Further, the response to bacterial 
plaque accumulation, periodontal inflammation and destruction was more severe in obese 
animals (Perlstein and Bissada, 1977). 
This association has largely been supported by epidemiological studies in 
Brazilian, Japanese and US populations. Saito et al. was the first to find an association 
between obesity and periodontal disease in humans (Saito et al. 1998). A periodontal 
assessment of 241 healthy Japanese by applying the community periodontal index of 
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treatment needs (CPITN), led to determine that the relative risk for periodontitis in 
overweight persons (BMI 25-29.9 kg/m
2
) was 3.4 and 8.6 in obese persons, after 
adjustment for age, gender, oral hygiene status and smoking (Saito et al. 1998). In fact, 
one study suggested that obesity is the second strongest risk factor, after smoking, for 
periodontal disease (Nishida et al. 2005). Studies have also reported that fat distribution 
is a significant consideration in the association with periodontitis. High upper body 
obesity and high total body fat were correlated with a higher risk of periodontal disease, 
compared with normal weight (Saito et al. 2001).  NHANES III data demonstrated that 
waist-to-hip ratio, BMI, fat-free mass, and log sum of subcutaneous fat significantly 
correlated with periodontal disease (Wood et al. 2003). Further analysis of the NHANES 
III data shows that BMI positively correlated with severity of periodontal attachment loss 
and that this relationship was modifiable by insulin resistance (Genco et al. 2005). 
 
Diabetes and Periodontal Disease 
Several well-characterized adipokines are essentially the same as pro-
inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-
6). Obese individuals have elevated production of TNF- α and IL-6 and these increases 
are also important in the pathogenesis of insulin resistance (Festa et al. 2003). In addition, 
increased levels of inflammatory cytokines lead to increased C-reactive protein (CRP) 
production in the liver, which may impact insulin resistance as well (Gabay et al. 1999). 
Recruited macrophages, in co-operation with adipocytes, secrete large quantities of 
proinflammatory cytokines, leading to the formation of a vicious inflammatory cycle 
(Nishimura et al. 2000). 
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Impaired Fasting Glucose and Periodontal Disease 
Impaired fasting glucose (IFG) refers to a condition in which the fasting blood 
glucose is elevated above normal levels but is not high enough to be classified as diabetes 
mellitus. It is a pre-diabetic state and has been associated with insulin resistance and 
increased risk of cardiovascular pathology. IFG can possibly progress to NIDDM. More 
recently, studies have begun to analyze the relationship between periodontal disease and 
the past development of glucose intolerance (Saito et al. 2004). Saito and colleagues 
assessed a group of 961 community-dwelling Japanese subjects aged 40-79 years and 
subsequently examined their glucose tolerance test results from 10 years earlier. A total 
of 415 subjects were identified with normal glucose tolerance, of which over the course 
of a decade, 72 developed glucose intolerance and nine subjects developed diabetes. In a 
multivariate analysis, it was concluded that impaired glucose tolerance was significantly 
associated with deeper periodontal pockets (Saito et al. 2004). 
Previous epidemiological studies assessing the association between obesity and 
periodontal disease have been able to relate an obese BMI to increased risk for 
periodontal disease based solely on BMI measurement and adipose tissue distribution. 
This study will contribute novel findings regarding the associations of systemic 
inflammatory markers in gingival crevicular fluid and serum concerning DARIC 
participants categorized as non-obese and obese according with their periodontal status. 
To date, no other study with such an impressive number of study participants has been 
able to study the relationship between obesity and periodontal disease at the 
inflammatory level. 
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AIM 
The proposed study examined the association between periodontal disease and 
two metabolic disorders (obesity defined as a BMI of >30kg/m
2
; IFG defined as a fasting 
plasma glucose level from 5.6mmol/L (100 mg/dL) to 6.9 mmol/L (125 mg/dL)), using a 
cross-sectional observational study design.   
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HYPOTHESIS 
The investigators hypothesized that both obesity and IFG (outcome variables) 
were associated with periodontal disease (exposure variable). Furthermore, it was 
presumed that the association between obesity and periodontitis was likely mediated 
through systemic inflammation and both these associations were likely modified by the 
extent of periodontal destruction. 
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MATERIALS AND METHODS 
Study Population 
The study cohort was selected from ARIC study participants attending Visit 4.  
Inclusion criteria were stipulated: (1) participants were aged ≥40 years at Visit 1, (2) 
participants must have been dentate and had both dentate status information and a 
periodontal examination at Visit 4, (3) participants must have had BMI measurements at 
Visit 4, and (4) participants must have had a serum sample available at Visit 4 in order to 
measure systemic inflammatory markers. No exclusion criteria were defined.  
Cases were defined as patients presenting with periodontal disease. The presence 
of periodontal disease was determined based on the Centers for Disease Control and 
Prevention-American Academy of Periodontology (CDC-AAP) definitions for disease 
(Page and Eke, 1997) and the Biofilm-Gingival Interface (BGI) classification of disease 
(Offenbacher et al. 2007). Non-cases were defined as patients without periodontal disease 
and were identified from the same study population.   
 
Variables of Interest 
Obesity: Obesity status was determined by the Body Mass Index (BMI) whereby 
>30kg/m
2
 is classified as obese. All participants with a BMI of <30kg/m
2
 were clustered 
into one category labeled as non-obese while all those with a BMI >30kg/m
2
 were labeled 
as obese. 
15 
 
Impaired fasting glucose (IFG): IFG (or impaired fasting glycemia) was 
determined using the World Health Organization (WHO) definition of fasting plasma 
glucose level from 5.6 mmol/L (100 mg/dL) to 6.9 mmol/L (125 mg/dL). Euglycemic or 
normal fasting glucose is from 3.9 mmol/L (70 mg/dL) to 5.5 mmol/L (99 mg/dL), 
whereas a person is considered to have diabetes when testing on more than one occasion 
as >7.0 mmol/L (>126 mg/dL). 
Periodontal status: Periodontal status was assessed according to the AAP-CDC 
definition of periodontal disease (Table 1A) and the BGI classification of periodontal 
disease (Table 1B) which does not incorporate attachment level measurements. 
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TABLE 1A & 1B 
 
Table 1A. CDC-AAP Definition of Periodontal Disease 
 
Disease Category Clinical Criteria 
Severe periodontitis >2 interproximal sites with clinical attachment loss (CAL) 
>6mm (not on the same tooth) AND 
>1 interproximal sites with probing depths (PD) >5mm 
  
Moderate periodontitis >2 interproximal sites with clinical attachment loss (CAL) 
>4mm (not on the same tooth) OR  
>2 interproximal sites with probing depths (PD) >5mm (not 
on the same tooth) 
 
No or mild periodontitis Neither “moderate” nor “severe” periodontitis 
 
 
Table 1B. BGI Classification of Periodontal Disease 
 
Disease Category Clinical Criteria 
P3 subjects have one or more PD >4mm with extent BOP >50% 
 
P2 one or more PD >4mm with extent BOP 10-50% 
 
P1 one or more PD >4mm with extent BOP<10% 
 
Gingivitis subjects have all PD <3mm and extent BOP >10% 
 
Healthy subjects with all PD <3mm and extent BOP <10% 
 
 
 
 
 
 
 
 
17 
 
Systemic inflammatory markers: The following markers of systemic inflammation 
were measured in serum samples from Visit 4: high-sensitivity interleukin (IL)-6, high 
sensitivity C-reactive protein (CRP), and soluble intercellular adhesion molecule 
(sICAM)-1.  All three markers have been demonstrated to be valid markers of acute 
systemic inflammation or infection.  In addition, 8-PGF2α (d8iso) and a soluble form of 
CD14 (sCD14) were also assessed. 
Other Potential Confounders: The following variables were also examined as 
potential confounders of the association between obesity and periodontal disease (or IFG 
and periodontal disease): race and ethnicity, trial center, gender, age, diabetes, smoking 
(5-levels), hypertension, education (3-levels), and income (3-levels). In addition, marital 
status, alcohol intake and dental care were also considered. These variables were 
collected by the parent ARIC study during Visit 4.   
 
Statistical Methods  
Descriptive statistics were performed using chi-square analysis and t-tests. 
Generalized logit regression will be used to examine the association between obesity or 
IFG among subjects without diabetes and periodontal disease status. The exposure 
variables, which are obesity or impaired fasting glucose (IFG), will be examined as 
dichotomous variables (e.g., non-obese vs. obese; IFG vs. euglycolic). Multiple logistic 
regression models will be used to control for confounding. The effects of interaction on 
periodontal status will be explored including potential interactions between IFG and 
obesity. In the generalized logistic models, each non-reference category was contrasted 
18 
 
with the reference category.  In this case, each combination of obesity and diabetes status 
was contrasted with the group that was both non-obese and non-diabetic group. 
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RESULTS 
Study population demographics 
The study sample included 6780 subjects, recruited from four study centers, with 
a mean age of 62.7 years in the non-obese group and 61.8 years in the obese group (Table 
2). A greater proportion of non-obese people presented to Visit 4 as non-diabetic and 
non-hypertensive in comparison to the obese study population (P <0.0001). In addition, 
the majority of non-obese subjects had an advanced education level and high income in 
comparison to the obese group (P <0.0001). A statistically significant difference between 
current heavy smokers and current drinkers was found between the groups with the 
majority in the non-obese group (P <0.0001). The majority of non-obese study 
participants were currently under the care of a dentist (68.1%), sought routine dental care 
(70.9%) and their last examination was less than one year ago (69.5%). All factors were 
statistically significant in comparison to the obese participants (P <0.0001). 
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TABLE 2 
 
Table 2. Relationship of Study Variables to Obesity in the ARIC Study Visit 4 
(N=6780) 
 Non-Obese Obese P-value 
 N* (%) N* (%)  
Race/Center     <0.0001 
Jackson, MS 574  (50.6%) 560  (49.4%)  
Washington County, MD 1116  (65.9%) 577  (34.1%)  
Minneapolis, MN 1483  (68.6%) 672  (21.2%)  
Forsyth County, NC      
  NC African-American 88  (64.7%) 48  (35.3%)  
  NC Caucasian 1244  (77.1%) 369  (22.9%)  
      
Gender     0.002 
Female 2403  (65.3%) 1276  (34.7%)  
Male 2135  (68.9%) 966  (31.2%)  
      
Mean Age (StdDev) 62.7  (5.71) 61.8  (5.41) <0.0001 
      
Married 3599  (67.8%) 1713  (32.3%) 0.005 
Un-Married 924  (63.9%) 523  (36.1%) 0.005 
      
Education     <0.0001 
Basic 534  (58.4%) 381  (41.6%)  
Intermediate 1958  (67.2%) 957  (32.8%)  
Advanced 2041  (69.4%) 900  (30.6%)  
      
Income     <0.0001 
Low 987  (60.3%) 650  (39.7%)  
Medium 1634  (67.9%) 774  (32.1%)  
High 1754  (70.8%) 725  (29.3%)  
      
Diabetes mellitus†     <0.0001 
Yes 422  (45.1%) 514  (54.9%)  
No 4094  (70.6%) 1704  (29.4%)  
      
Hypertension‡     <0.0001 
Yes 1270  (55.2%) 1032  (44.8%)  
No 3250  (73.0%) 1200  (27.0%)  
      
Smoking     <0.0001 
 Never 2047  (64.6%) 1121  (35.4%)  
 Former Light 1006  (68.8%) 457  (31.2%)  
 Former Heavy 706  (63.7%) 403  (36.3%)  
 Current Light 118  (71.1%) 48  (28.9%)  
21 
 
 Current Heavy 486  (78.9%) 130  (21.1%)  
 
Current Drinker 
    <0.0001 
    Yes 2589  (71.0%) 1059  (29.0%)  
    No 1937  (62.2%) 1175  (37.8%)  
      
Under care of dentist     <0.0001 
No 415  (57.6%) 306  (42.4%)  
Yes 4097  (68.1%) 1923  (31.9%)  
      
Routine dental care     <0.0001 
Regular DDS Utilization 3499  (70.9%) 1437  (29.1%)  
Episodic DDS Utilization 1016  (56.1%) 794  (43.9%)  
      
Last dental visit     <0.0001 
 < 1year 3643  (69.5%) 1600  (30.5%)  
 > 1year 869  (58.1%) 627  (41.9%)  
*Totals not equal to N due to missing values. 
†Fasting blood glucose >126 mg/dL, nonfasting >200 mg/dL, or self-reported history of 
diabetes, or evidence of diabetes medications. 
‡Systolic >140 or diastolic >90 mmHg. 
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Periodontal measures of disease and obesity 
A statistically significant difference between periodontal health and obesity was 
found in this population (Table 3). A greater percentage of non-obese participants had 
healthy periodontium while a greater proportion of obese patients presented with severe 
disease according to both the CDC-AAP definition for periodontal disease (P = 0.02) and 
BGI classification (P <0.0001). A greater percentage of sites with probing depths (PD) 
>4mm and attachment loss (AL) >3mm was found in obese patients and this difference 
was statistically significant (P <0.0001). Similarly, a greater proportion of obese subjects 
presented with higher scores for percentage of bleeding on probing, Gingival Index (GI) 
score >1 and a Plaque Index (PI) score >1 (P <0.0001). However, when mean extent of 
PD>4mm, AL>3mm and BOP was adjusted for plaque score, the associations were no 
longer significant. 
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TABLE 3 
 
Table 3. Relationship of Periodontal Measures of Disease and Obesity in the ARIC 
Study Visit 4 (N=6731) 
 
Case Definitions Non-Obese 
N* (%) 
Obese 
N* (%) 
P-value 
CDC-AAP Definition      0.02 
 Severe 760  (16.7%) 421  (18.7%)  
 Entry 1852  (40.8%) 941  (41.9%)  
 Healthy or Mild 1926  (42.4%) 880  (39.2%)  
      
BGI Classification      <0.0001 
P3 538  (11.8%) 340  (15.1%)  
P2 1767  (38.9%) 925  (41.2%)  
P1 894  (19.7%) 323  (14.4%)  
Gingivitis 675  (14.8%) 349  (15.5%)  
Healthy 664  (14.6%) 305  (13.6%)  
      
Mean (StdDev) Extent PD >4mm 6.92  (11.3) 8.27  (12.5) <0.0001 
Mean (StdDev) Extent AL >3mm 22.5  (22.8) 24.8  (23.8) <0.0001 
Mean (StdDev) Extent BOP 24.1  (22.9) 28.0  (25.0) <0.0001 
Mean (StdDev) Extent GI >1 30.3  (38.2) 43.2  (42.7) <0.0001 
Mean (StdDev) Extent PI >1 38.2  (36.9) 51.5  (39.4) <0.0001 
*Totals not equal to N due to missing values; column percents presented. 
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Serum and GCF inflammatory mediators and obesity 
Statistically significant differences in valid markers of acute systemic 
inflammation or infection were found. Notably, CRP (P <0.0001), IL-6 (P <0.0001) and 
sICAM-1 (P = 0.02) were increased in the obese group (Table 4). Mean log serum 
mediators were stratified by the CDC-AAP definition and BGI classification of 
periodontal disease. CRP and IL-6 reached significance in all levels of disease suggesting 
that increased levels of these pro-inflammatory cytokines with obesity is independent of 
periodontal status and a true representation of systemic inflammation. In the CDC-AAP 
moderate periodontitis group, D8Iso (P= 0.04), sICAM-1 (P= 0.04) were significant 
along with CRP and IL-6 (data not shown).  
GCF was collected from 179 participants to assess various inflammatory 
mediators (PGE2, IL-1ra, IL-1B, 1L-4, IL-5, IL-6, IL-8, 1L-10, TNFα, gCSF, MIP1a, 
MIP1b, RANTES, MCP1, IFNγ, IL-17, ENA78). No significant differences were 
observed between groups for all tested. 
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TABLE 4 
Table 4. Mean Log Serum Mediators (StdDev) by Obese Status in the ARIC Study 
 Non-Obese 
(StdDev) 
Obese 
(StdDev) 
P-value 
CRP          (N=5596) 0.55 (0.42) 0.75 (0.44) <0.0001 
IL-6           (N=5527) 0.37 (0.24) 0.46 (0.24) <0.0001 
D8Iso        (N=4893) 3.69 (1.87) 3.78 (1.85) 0.09 
sICAM-1   (N=5516) 2.34 (0.33) 2.37 (0.34) 0.02 
sCD14       (N=1292) 6.19 (0.32) 6.17 (0.29) 0.14 
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Periodontal measures of disease, obesity and diabetic status 
In a generalized logit model, where the reference group had both non-obese and 
non-diabetic participants, the odds ratio was calculated for likelihood of having 
periodontal disease. Using the CDC-AAP definition of periodontal disease, a significant 
odds ratio was found in participants with moderate and severe levels of disease who were 
non-obese and diabetic (moderate level OR=1.64, 95%CI 1.30-2.08; severe level 
OR=2.04, 95%CI 1.54-2.69), and obese and diabetic (moderate level OR=1.39, 95%CI 
1.13-1.71; severe level OR=1.62, 95%CI 1.26-2.10) (Table 5a). Obese participants had an 
increased likelihood for severe level of disease (OR 1.24, 95%CI 1.04-1.49) despite being 
non-pre-diabetic and non-diabetic. An increased odds for gingivitis was identified when 
using the BGI classification for participants that were non-obese and diabetic. In a fully 
adjusted model, an increased likelihood for gingivitis was found in obese participants that 
were euglycemic or had diabetes (Table 5b). Increased risk for BGI-P3 disease was found 
in patients that were non-obese and had diabetes and for all levels of glycemic control in 
the obese participants. 
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TABLE 5A 
Table 5a. Logistic Regression Models of the Crude Associations between Obesity, 
Glycemic Control with Periodontitis Case Status According to Euglycemic, IFG and 
Diabetes Status 
 
 Non-Obese (OR 95%CI)* Obese (OR 95%CI)* 
 IFG Diabetic Euglycemic IFG Diabetic 
CDC-AAP Definition† 
Moderate  1.23 
(0.97-1.56) 
1.64 
(1.30-2.08) 
1.12 
(0.98-1.29) 
1.18 
(0.93-1.48) 
1.39 
(1.13-1.71) 
Severe  1.27 
(0.94-1.73) 
2.04 
(1.54-2.69) 
1.24 
(1.04-1.49) 
1.32 
(0.98-1.76) 
1.62 
(1.26-2.10) 
 
BGI Classification†† 
Gingivitis 
0.97 
(0.66-1.43) 
2.09 
(1.40-3.12) 
1.15 
(0.90-1.45) 
1.31 
(0.90-1.89) 
1.35 
(0.96-1.91) 
P1 
0.79 
(0.55-1.14) 
1.17 
(0.78-1.77) 
0.851 
(0.67-1.07) 
0.64 
(0.43-0.95) 
0.73 
(0.51-1.05) 
P2 
0.91 
(0.66-1.25) 
1.48 
(1.03-2.13) 
1.21 
(1.00-1.48) 
1.09 
(0.79-1.50) 
1.18 
(0.88-1.59) 
P3 
1.23 
(0.83-1.82) 
2.95 
(1.97-4.39) 
1.38 
(1.07-1.76) 
1.67 
(1.15-2.44) 
2.16 
(1.54-3.03) 
* Reference group= non-obese, non-pre-diabetic, non-diabetic subjects 
† Reference group= health-mild periodontitis 
†† Reference group= healthy 
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TABLE 5B 
 
Table 5b. Logistic Regression Models of the Fully Adjusted Associations between 
Obesity, Glycemic Control with Periodontitis Case Status According to Euglycemic, 
IFG and Diabetes Status 
 
 Non-Obese (OR 95%CI)* Obese (OR 95%CI)* 
 IFG Diabetic Euglycemic IFG Diabetic 
CDC-AAP Definition† 
Moderate   1.10  
(0.85-1.41) 
1.58  
(1.23-2.03) 
1.23  
(1.06-1.43) 
1.21  
(0.94-1.55) 
1.50  
(1.19-1.89) 
Severe  0.96  
(0.68-1.35) 
1.65  
(1.21-2.26) 
1.41  
(1.16-1.73) 
1.24  
(0.90-1.72) 
1.59  
(1.19-2.14) 
BGI Classification† 
Gingivitis 0.83  
(0.55-1.26) 
1.94  
(1.27-2.95) 
1.39  
(1.07-1.80) 
1.48  
(0.99-2.21) 
1.81  
(1.24-2.64) 
P1 0.82  
(0.55-1.22) 
1.24  
(0.79-1.94) 
0.98  
(0.76-1.26) 
0.71  
(0.46-1.10) 
1.02  
(0.67-1.53) 
P2 0.83  
(0.58-1.17) 
1.58  
1.08-2.32) 
1.55  
(1.25-1.92) 
1.23  
(0.86-1.74) 
1.70  
(1.21-2.37) 
P3 0.88  
(0.57-1.36) 
2.28  
(1.49-3.50) 
1.67  
( 1.27-2.19) 
1.56  
(1.03-2.38) 
2.31  
(1.57-3.39) 
* Reference group= non-obese, non-pre-diabetic, non-diabetic subjects 
† Reference group= health-mild periodontitis 
†† Reference group= healthy 
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DISCUSSION 
Periodontitis has long been considered a chronic inflammatory disease instigated 
by mostly anaerobic Gram-negative bacterial insult leading to gingival inflammation and 
bone resorption (Socransky and Haffajee, 1992). The classic model of periodontal disease 
has been altered due to emerging evidence that indicates systemic diseases may also 
influence the cellular and molecular mechanisms involved in periodontal pathogenesis. 
Numerous epidemiological studies have assessed these relationships between periodontal 
disease and systemic diseases. Of interest, associations between obesity and periodontitis 
have been demonstrated in population studies (Saito et al. 1998, 2001, 2004; Genco et al. 
2005; Nishida et al. 2005). To our knowledge, the current available literature fails to 
demonstrate underlying biological mechanisms that may further elucidate the relationship 
between these chronic inflammatory diseases. We sought to examine the association 
between periodontal disease and metabolic disorders like obesity and IFG while also 
providing information on systemic and GCF inflammatory mediator production. 
The periodontal status of DARIC study participants was classified using two 
different methods. The CDC-AAP definition (Page and Eke, 1997), which records 
probing depths and attachment loss, classifies patients as healthy-mild periodontitis, 
moderate periodontitis and severe periodontitis. It uses clinical measures alone to 
determine a patient’s periodontal disease level whereas the BGI classification system was 
created by considering clinical measures of probing depth and BOP as those measures 
relate to microbial, inflammatory and host-response data for these subjects (Offenbacher 
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et al. 2007). With this classification, patients are categorized not only by clinical 
measurements but clustered according to biologic phenotypes. 
Serum and GCF was collected at ARIC Visit 4 to detect important markers of 
acute systemic inflammation or infection. Increased levels of CRP, IL-6 and sICAM-1 
were detected in obese DARIC participants and statistically significant differences were 
present compared to the non-obese subset of patients. We sought to determine if 
increased mediator production was present at a local and/or systemic level thus 
implicating local tissue effects due to periodontal disease or systemic inflammatory 
burden from an obese status. In so doing, detection of mediators was stratified by 
periodontal status (CDC-AAP definition or BGI classification). Overall, CRP and IL-6 
remained significant in any level of disease in obese patients and only participants 
classified with moderate level (CDC-AAP) approached significance with other mediators 
such as D8Iso (P= 0.04), sICAM-1 (P= 0.04) and sCD14 (P= 0.06). The evidence from 
this study therefore suggests that important pro-inflammatory mediators like CRP and IL-
6 have increased production solely due to obesity status and periodontal disease severity 
does not significantly alter these levels or levels of other mediators.  
These findings reaffirm discoveries from previous studies regarding the 
importance of CRP and IL-6. IL-6 production has been linked to periodontal disease 
destruction by activating osteoclasts and promoting osteoclastic bone resorption 
(Yamamoto et al. 1997). CRP is produced by the liver in response to inflammatory 
factors produced and released by adipocytes (Lau et al. 2005). Recent results from a pilot 
study in the Periodontitis and Vascular Events (PAVE) Study indicated the importance of 
obesity on CRP levels (Offenbacher et al. 2009). An earlier study on the ARIC 
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population (Slade et al. 2003) showed that extensive periodontal disease and BMI were
 
jointly associated with increased CRP levels. In our study, CRP levels in the obese 
population compared to normal weight remained significant even in patients with 
healthy-mild periodontitis.  
No significant differences were observed in GCF measurements according to BMI 
or glycemic control. This may suggest that the local effect of glycemia may not be as 
important as previously thought in this study population. Conversely, Lalla et al. (2001) 
implied that the receptor for advanced glycation end products (RAGE), expressed on 
endothelium and mononuclear phagocytes, plays a crucial role in oral infection and 
inflammatory responses in a hyperglycemic state or diabetes. Similarly, diabetes has been 
shown to modulate gene expression in the gingival tissues of patients with chronic 
periodontitis (Duarte et al. 2007). Increased  mRNA levels for IL-1B, IL-1ra, IL-6, IL-8, 
IFN-γ and RANKL were found in those gingival tissues, while IL-10 and osteoprotegerin 
expressed was decreased in diseased tissues. In this study, GCF was collected in a much 
smaller subset of participants (n=179) and this alone may make it difficult to assess any 
true differences between groups.  
The association between obesity status (non-obese or obese), glycemic control 
(euglycemic, IFG or diabetic) and periodontal disease (CDC-AAP or BGI classification) 
was assessed. The role of glycemic control was shown in this study. Generally, 
participants with diabetes had increased odds for gingivitis and for CDC-AAP severe 
level or BGI-P3 level of disease, regardless of BMI. For the first time, it was 
demonstrated that participants with diabetes have increased risk for gingivitis as well as 
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periodontal disease (Figure 2). Interestingly, non-obese patients that had impaired fasting 
glucose did not present with an increased risk for any level of periodontal disease. 
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FIGURE 2 
 
 
 
Figure 2: The association between diabetes, obesity and periodontal disease: the 
estimated odds of gingivitis and P3 (BGI) in non-obese diabetics (solid red) and obese 
diabetic (dashed red) DARIC participants. 
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In addition, it was shown that euglycemic obese participants have an increased 
risk for gingivitis (adjusted OR 1.39, 1.07-1.80) and CDC-AAP severe level or BGI-P3 
level of periodontal disease (adjusted OR 1.67, 1.27-2.19)  (Figure 3). It remains 
important to recognize that this increased risk was in the presence of normal glucose 
levels suggesting that the systemic inflammatory burden of obesity alone may contribute 
to this increased risk.  Data from participants in the NHANES III study similarly present 
an adjusted odds ratio for having periodontal disease in obese subjects of 1.76 (1.18-2.61) 
(Al-Zahrani et al 2003). While the study participation was impressive in NHANES III 
(n=13 665), their definition for periodontal disease and half-mouth periodontal 
examinations likely underestimated disease presence.  
The biological mechanisms that relate obesity and periodontitis largely remain 
unclear but we have shown consistently in this study increased and statistically 
significant differences in CRP and IL-6 production in the obese participants compared to 
the non-obese. Potentially contributing further to disease pathogenesis are the secretion of 
adipokines (leptin, adiponectin) and pro-inflammatory cytokines (TNF-α, plasminogen 
activator inhibitor 1, in addition to IL-6) secreted from adipose tissue and having 
paracrine and endocrine functions (Furugen et al. 2010). Toll-like receptor 4 (TLR4) 
present in adipocytes can either be stimulated by LPS or free fatty acids and subsequently 
enhances production of TNF-α and Il-6 which also contribute to systemic insulin 
resistance (Song et al. 2006). 
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FIGURE 3 
 
 
 
Figure 3: The association between obesity and periodontal disease: the estimated 
odds of gingivitis and P3 (BGI) in obese non-pre-diabetic and non-diabetic DARIC 
participants.  
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
In the crude model (Table 5a) and the fully adjusted model (Table 5b), the P1 
level participants did not show any increased risk for disease regardless of BMI or 
glycemic control. The level of plaque removal and better home care exemplified by P1 
patients indicates that periodontal disease prevention is achievable despite other systemic 
influences that may increase risk for disease, namely obesity and diabetes. 
The principle limitation of this study is its cross-sectional design. Causality 
therefore cannot be implied and only an association between obesity and periodontal 
disease or diabetes and periodontal disease was shown. Future studies should have 
longitudinal designs to determine if obesity is a risk factor for periodontitis. Secondly, 
dental history information was collected only at Visit 4. It was probable that study 
participants lost their teeth several years prior to attending the Visit 4 examination. Bias 
may have been introduced as a consequence of assuming that all edentulous patients lost 
their teeth at the time dental history was obtained. Patients included in DARIC had to 
have complete dental and periodontal examination information at Visit 4. This may 
introduce bias due to differential loss to follow-up prior to Visit 4 with respect to dentate 
status.  Additionally, the only measure of obesity status in this study was BMI. Certainly 
participants who may have presented with a large muscle mass and high height to weight 
ratio would have been incorrectly categorized as obese despite possibly having low body 
fat. Other anthropometry measures like waist circumference and waist to hip ratio would 
have strengthened the finding of an obese status. Future investigations may seek to 
incorporate more measures of obesity status. Nevertheless, this study has many strengths 
namely, a large study population was recruited and data regarding other potential 
confounders is available from the parent study. It also should be noted that study subjects 
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were not patients, but were originally selected during Visit 1 to be representative of their 
community. 
In conclusion, we found important associations between diabetes and periodontal 
disease as well as obesity and periodontal disease. For the first time, we showed that 
increased likelihood for gingivitis to be present in both subjects with diabetes and an 
obese BMI. Reaffirmation of the critical role of CRP and IL-6 on systemic inflammatory 
burden was shown in an obese population. These results further elucidate the importance 
of relationships between oral and systemic disease. Prevention and management of 
obesity and diabetes should be considered as adjunctive treatment approaches to 
improving overall oral health. 
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DIFFERENTIAL EXPRESSION OF MICRORNA SPECIES IN OBESE 
PATIENTS AS A POTENTIAL MODIFIER OF PERIODONTAL 
INFECTION PATHOGENESIS 
 
Abstract 
Obesity is an established risk factor for periodontitis but our understanding of the 
molecular pathogenesis of obesity as it relates to periodontal disease pathogenesis is 
unknown. Many microRNA (miRNA) species that post-transcriptionally modulate the 
expression of genes linked to regulation of metabolism are abnormally expressed in 
obesity and it is possible that they impact periodontal pathogenesis. This is important 
given the recent evidence implicating specific miRNA species as modifiers of 
inflammatory pathways.  
AIMS: The overall goal is to integrate genetic, bioinformatic and epigenetic 
approaches in order to identify miRNAs and their collaborative networks involved in 
obesity as a modifier of periodontal infection pathogenesis. The specific aims include:  
(1) to determine if diseased periodontal tissues biopsied from patients with periodontal 
disease express unique miRNAs compared to biopsies obtained from non-diseased, 
healthy subjects; and (2) to determine whether Body Mass Index (BMI) will influence the 
miRNA expression patterns in biopsies from diseased periodontal tissues as compared to 
periodontal biopsy samples obtained from non-diseased, non-obese subjects. 
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METHODS: Total RNA was extracted (miRNeasy, Qiagen) from gingival biopsy 
samples collected from 24 subjects: 12 non-obese (BMI <30kg/m
2
) patients and 12 obese 
(BMI >30kg/m
2
) patients, each group with 6 periodontally healthy sites and 6 chronic 
periodontitis sites. miRNA expression patterns were assessed using a human genome RT
2
 
miRNA PCR array (SABiosciences) which contained probes for 88 of the most 
abundantly expressed and best characterized miRNA sequences in the human miRNA 
genome. Data obtained was analyzed using four miRNA databases to identify potential 
target genes of important miRNAs expressed in this study. 
RESULTS: Eleven unique miRNAs were identified (miR-15a, -18a, -22, -30d, -
30e, -103, -106b, -130a, -142-3p, -185, -210), whereby the majority were up-regulated in 
the periodontally disease and obese group. Sixty-nine different genes with miRNA target 
sequences were identified which included proinflammatory cytokines/chemokines, 
proteins involved in collagen formation, glucose and lipid metabolism.  
CONCLUSION: The miRNAs identified in this study may play a crucial role in 
the pathogenesis of periodontal infection modified by obesity as well as provide a basis 
for further investigations regarding the effect of obesity on periodontal pathogenesis. In 
doing so, these miRNA may represent novel therapeutic targets.  
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INTRODUCTION 
Obesity has reached epidemic proportions globally in adults and children alike, 
and is a major contributor to the global burden of chronic illness and disability (Mealey 
and Ocampo 2007).
 
The chronic imbalance between food intake and energy expenditure 
leads to obesity (Clément 2006). Research has shown that a multitude of gene 
polymorphisms can determine a person’s susceptibility to weight gain (Adair and 
Prentice 2004).
 
Gene expression of these key susceptibility genes can be influenced by 
epigenetic and environmental factors (Emilsson et al. 2008). Transcription factors and 
microRNAs (miRNAs) are the most abundant regulatory systems. Evidence from in vitro 
studies and more recently, from human studies, have identified specific miRNAs that are 
associated with obesity.  
The role of miRNAs in adipocyte development and lipid metabolism has been 
investigated in mouse models and on cultured human preadipocytes. Convincing 
evidence from these studies has indicated that miR-27a, -103 and -143 are important in 
adipocyte differentiation (Esau et al. 2004; Lin et al. 2009; Kim et al. 2009; Xie et al. 
2009). Expression of miR-27 is capable of suppressing PPARγ and C/EBPα, two very 
important early regulators of adipogenesis (Lin et al. 2009; Kim et al. 2009). miR-143 
expression was up-regulated 3.3-fold in obese mice with similar increases in adipocyte 
differentiation markers peroxisome proliferator-activated receptor-γ (PPARγ) and 
adipocyte fatty acid-binding protein (aP2) (Takanabe et al. 2008). Using microarray 
analysis, an up-regulation of miR-335 was detected in obese mice. miR-122 was 
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determined to be an important regulator of cholesterol and fatty-acid metabolism (Esau et 
al. 2006).  
miRNA expression in human adipose tissue was first studied by Klöting et al. 
(2009) and significant correlations between expression of miRNA-17-5p, -132, -99a, -
134, 181a, -145, -197 and adipose tissue morphology, metabolic parameters (ie. HbA1c, 
fasting plasma glucose) and leptin, adiponectin and IL-6 levels. More recently, another 
human study showed that miR-519d was up-regulated in an obese population and its 
predicted target was peroxisome proliferator-activated receptor-α (PPARA) (Martinelli et 
al. 2010). 
Obesity is an established risk factor for periodontitis (Saito et al. 2001, 2005; Al-
Zahrani et al. 2003; Wood et al. 2003; Lundin et al. 2004; Della Vecchia et al. 2005; 
Genco et al. 2005; Nishida et al. 2005) but our understanding how obesity modifies 
periodontal disease pathogenesis at the molecular level is unknown. Many miRNA 
species that post-transcriptionally modulate the expression of genes regulating 
metabolism are abnormally expressed in obesity. Recently, some of these miRNA species 
have been identified as possible modifiers of inflammatory pathways (Emilsson et al. 
2008; Iliopoulos et al. 2008). More specifically, inhibition of miR-22 causes up-
regulation of PPARA and BMP7, blocked the inflammatory process through inhibition of 
IL1B and promoted repair in osteoarthritic chondrocytes (Iliopoulos et al. 2008). 
Data regarding potential miRNA regulation of periodontal pathogenesis, a chronic 
inflammatory disease, is very limited. Only one published animal report (Nahid et al. 
2011) is available whereby Porphyromonas gingivalis, Treponema denticola, and 
Tannerella forsythia infected ApoE (-/-) mice showed remarkable miR-146a expression 
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and negative correlation with inflammatory cytokine TNF-α production. This preliminary 
animal study sheds light on the possible direct or indirect modulatory role of miRNAs on 
alteration of chronic periodontal pathology. To date, there is no available published data 
studying the differential expression of miRNAs in obese humans with periodontal 
disease. Findings from this study may enable us to discover key miRNA species involved 
in mediating the effect of obesity on periodontal pathogenesis. In so doing, we can target 
these miRNA for therapeutic interventions. 
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AIM 
The overall goal is to integrate genetic, bioinformatic and epigenetic approaches 
in order to identify miRNAs and their collaborative networks involved in obesity as a 
modifier of periodontal infection pathogenesis.  
The specific aims include:   
(1) to determine if diseased periodontal tissues biopsied from patients with 
periodontal disease express unique miRNAs compared to biopsies obtained from non-
diseased, healthy subjects; and  
(2) to determine whether BMI will influence the miRNA expression patterns in 
biopsies from diseased periodontal tissues as compared to periodontal biopsy samples 
obtained from non-diseased, non-obese subjects. 
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HYPOTHESIS 
It is hypothesized that there will be converging and diverging  miRNA expression 
patterns between gingival tissues obtained in obese patients with healthy periodontium vs 
obese patients with periodontal disease. Possible target genes for these altered miRNA 
profiles will be associated with inflammatory gene expression of PPARγ, NFκB and IL-6. 
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MATERIALS AND METHODS 
Study Participant Selection and Gingival Tissue Biopsies 
This study was approved by the Institutional Review Board at the University of 
North Carolina at Chapel Hill. A total of 24 participants, aged between 18 and 65 years, 
provided informed consent and were enrolled into this cross-sectional case-control study 
(Appendix A: Supplementary Materials and Methods). Height and weight measurements 
were collected on all recruited subjects in order to assess Body Mass Index (BMI). 
Participants were divided into two groups based on BMI. Group 1 consisted of 12 non-
obese subjects (BMI <30 kg/m
2
) and was further divided into two subsets: six patients 
with healthy periodontium and 6 patients with chronic periodontitis.  Group 2 consisted 
of 12 obese subjects (BMI >30 kg/m
2
) and was similarly divided into two subsets: six 
patients with healthy periodontium and 6 patients with chronic periodontitis. Overall, 
four main groups of participants were identified: (1) non-obese and periodontally healthy 
(n=6), (2) non-obese and periodontally diseased (n=6), (3) obese and periodontally 
healthy (n=6), and (4) obese and periodontally diseased (n=6). Identified subjects with a 
healthy periodontium or chronic periodontitis were ineligible to participate if they had 
chronic systemic diseases which also had oral manifestations, active infectious systemic 
diseases or significant oral damage, gross oral pathology or severe unrestored caries, 
needed prophylactic antibiotics or were treated with antibiotics for any condition within 1 
month prior to the periodontal examination or, were taking medication known to affect 
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the periodontium (e.g., phenytoin, calcium antagonists, cyclosporin, coumadin, non-
steroidal anti-inflammatory drugs, aspirin >81mg) within one month of the examination.  
Comprehensive periodontal examinations were performed on all participants and 
probing depths (PDs), clinical attachment level (CAL) and bleeding on probing (BOP) 
was recorded at six sites per tooth. In patients categorized as having a healthy 
periodontium, a biopsy was taken from an interproximal site with a PD <4mm, no BOP 
and no radiographic evidence of bone loss. Sites biopsied from patients with chronic 
periodontitis had a PD >5mm, BOP and radiographic evidence of bone loss. Gingival 
biopsy samples were immediately placed in RNAlater
®
 (Applied Biosystems/Ambion 
Inc., Austin, TX) overnight at 4°C and stored at -80ºC.  
 
RNA Isolation and Quantitative Real-Time Reverse Transcription-PCR 
 Total RNA, including small RNAs, was isolated from the collected gingival tissue 
samples using a TissueLyser LT and miRNeasy Mini Kit (Qiagen, Valencia, CA). RNA 
was quantified using the NanoDrop (Thermo Scientific, Wilminngton, DE) and quality 
and purity was assessed following isolation using the 2100 Bioanalyzer (Agildent, Foster 
City, CA). Based on these variables, the best 20 samples (n=5 per group based on BMI 
and periodontal status) were used for further analysis. Briefly, a volume of 600ng total 
RNA was used for reverse transcription reactions to generate complementary DNA 
(cDNA) using the RT
2
 miRNA First Strand Kit (SABiosciences, Frederick, MD) 
according to the manufacturer’s instructions. Quantitative real-time PCR (qRT-PCR) was 
performed with 100μL of synthesized cDNA, 1275μL 2x RT2 SYBR Green PCR Master 
Mix and 1175μL of ddH2O in a 7500 Sequence Detection System (ABI Prism, Applied 
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Biosystems, Carlsbad, CA).  MicroRNA expression patterns were assessed using a 
human genome RT
2
 miRNA PCR Array (Catalogue no. MAH-001A, SABiosciences, 
Frederick, MD) which contained probes for 88 of the most abundantly expressed and best 
characterized miRNA sequences in the human miRNA genome and 8 additional 
housekeeping genes (Appendix B: Array Layout).  
 
miRNA qRT-PCR Microarray Analysis and Target Selection 
 SNORD48 (Accession Number: NR_002745) and RNU6-2 (Accession Number: 
NR_002752) were used for normalization. Amplification parameters, conditions and 
melting curves were set by the manufacturer. Data were analyzed using the 2
-∆∆CT
 method 
(Livak & Schmittgen, 2001) and results were reported as fold regulation. miRNAs with a 
P-value <0.05 were selected for further investigation. In silico analysis was performed 
using  microCosm Targets Version 5 (http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/), TargetScan Release 5.1 (http://www.targetscan.org/), 
PicTar (http://pictar.mdc-berlin.de/) and microRNA.org Release August 2010 
(http://www.microrna.org/microrna/home.do) databases for computationally predicted 
targets of each of the statistically significant differentially expressed human miRNA. To 
ensure that true targets were identified for each miRNA, they were identified in 3 out of 4 
database systems utilized. 
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RESULTS 
Study Population Demographics 
 The mean participant age in this study population varied from 39.4 to 49.4 years 
and a large standard deviation is present in each category due to the wide age range of 
study participants included in the final analysis (18 to 64 years old) (Table 1). Smoking 
status of all patients was recorded. The majority were categorized as never smokers 
(60%), 35% considered themselves to be ex-smokers while only one participant in the 
non-obese and periodontally diseased subset presented as a current smoker. None of the 
participants had diabetes. Participants in each subset were not matched according to age, 
gender or race. The participants in the non-obese groups had mean BMIs of 24.8 and 25.3 
which is categorized as normal (BMI 18.5-24.9kg/m
2
) and slightly overweight (BMI 25-
29.9kg/m
2
). The participants in the obese subsets had mean BMIs which would be 
categorized as obese (BMI 30-34.9kg/m
2
) and severely obese (BMI 35-39.9kg/m
2
). 
Periodontal diagnosis was determined according to the criteria previously stipulated. 
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TABLE 1 
 
Table 1: Study participant demographics according to periodontal status and BMI 
(N=20, N=5/group) 
 
 Healthy Periodontium Periodontitis 
Variables Non-Obese 
N (%) 
Obese 
N (%) 
Non-Obese 
N (%) 
Obese 
N (%) 
Mean Age (StdDev) 39.4 (10.0) 49.4 (15.4) 46.6 (16.7) 48.8 (13.3) 
Gender 
Female 
Male 
 
4 (80%) 
1 (20%) 
 
2 (40%) 
3 (60%) 
 
3 (60%) 
2 (40%) 
 
3 (60%) 
2 (40%) 
Race 
Caucasian 
African-American 
Other 
 
5 (100%) 
0 
0 
 
4 (80%) 
1 (20%) 
0 
 
2 (40%) 
3 (60%) 
0 
 
3 (60%) 
0 
2 (40%) 
Mean BMI (StdDev) 24.8 (2.8) 34.6 (3.7) 25.3 (2.3) 36.1 (5.6) 
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Differential miRNA Expression in Participants with Periodontitis 
 A comparison between participants with a healthy periodontium (and non-obese) 
and participants with periodontitis (either non-obese or obese) indicated that there was an 
up-regulation of 10 miRNAs (N=5/group, P <0.05) (Figure 1). Generally, the fold 
regulation varied from 1.5 fold to 6.4 fold. The majority of miRNA expressed in the 
periodontitis group  reached statistical significance in those that were also obese. miR-
30e was the only unique miRNA to reach statistical significance in the periodontitis and 
non-obese group. miR-106b reached a high level of statistical significance (P <0.01) in 
the periodontitis participants regardless of their BMI classification suggesting a 
significant role in periodontitis pathogenesis. Nevertheless, the fold regulation was 
greater (6.4 fold) for the participants who were obese compared to the non-obese 
participants (4.9 fold) possibly implying an additive effect of an obese status.  
An assessment of the influence of periodontal status on miRNA expression in an 
obese population revealed that only two miRNA were differentially expressed and up-
regulated in diseased gingiva compared to healthy gingiva. miR-185 (3.0 fold, P=0.03) 
and miR-106b (2.5 fold, P= 0.02) expression was most significant in comparison to obese 
participants with a healthy periodontium. These same miRNA also reached statistical 
significance when compared to non-obese participants with a healthy periodontium 
however, the fold regulation was greater (miR-106b: 6.4 fold, P=0.001 and miR-185: 3.5 
fold, P=0.025). The quantitative differences in expression of miR-106b and miR-185 may 
be due to an underlying effect of obesity-related systemic inflammation. 
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Figure 1: Fold regulation of miRNA species observed in periodontitis participants 
according to BMI compared to participants with healthy periodontium (non-obese). 
  
  
 
 
 
 
 
 
 
 
Periodontitis (Obese) 
Periodontitis (Non-obese) 
*    P <0.05 
**  P <0.01 
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Differential miRNA Expression between Non-obese and Obese Participants  
 Using a similar control group, a comparison was made between participants who 
were non-obese (with a healthy periodontium) to participants that presented with an 
obese BMI (and either periodontally healthy or had periodontitis). An up-regulation was 
seen in 11 miRNA (N=5/group, P <0.05) (Figure 2). Fold up-regulation was similar to 
those observed when assessing differences in periodontal status. Overall, considerable 
up-regulation of numerous miRNA is observed in the participants who were obese and 
presented with periodontal disease. 
miR-18a was uniquely expressed in obese participants with a healthy 
periodontium. mR-106b expression did not reach statistical significance for the obese 
participants with healthy periodontium. Rather, within this sub-cohort, it was uniquely 
expressed in obese participants with periodontitis. This further strengthens the 
supposition that miR-106b may play an important role in periodontal infection 
pathogenesis. 
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FIGURE 2 
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Figure 2: Fold regulation of miRNA species observed in obese participants according to 
periodontal status compared to non-obese participants (healthy periodontium). 
 
 
 
 
 
 
 
 
 
 
Obese (Healthy Periodontium) 
Obese (Periodontitis) 
*    P <0.05 
**  P <0.01 
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Overall, 11 miRNA were identified with significant up-regulation in this study 
cohort (Table 2). Nine of these were expressed in the obese group with periodontal 
disease. This may suggest an additive effect of both chronic inflammatory conditions. 
 
Predicted mRNA Targets 
 mRNA targets linked to immunology, inflammation and metabolic disorders by 
GO Biological Process Term were determined for these 11 miRNA using four available 
miRNA databases. Predicted targets were considered validated if present in three out of 
four miRNA databases. Sixty-nine different genes with miRNA target sequences were 
identified for the 11 miRNA differentially expressed in this study (Appendix C: Predicted 
Genes and GO Terms). When including the targets validated in two out of three 
databases, a total of 139 different genes were identified (listed in boxed parentheses). The 
potential targets include key cytokines involved in systemic inflammation: members of 
the interleukin family (IL1A, IL1F9, IL31 [IL15, IL17B, IL1F8, IL20]) and receptors 
(IL13RA1, IL27RA [IL9R, IL10RB, IL1RL1, IL21R]), interferon family (IFNA16, 
IFNA21 [IFNA1, IFNA2, IFNK]) and receptor (IFNAR2, IRF2, IRF5), tumor necrosis 
factor superfamily (TNF, TNFAIP3, TNFSF8, TNFSF14 [TNFSF9]) and receptors 
(TNFRSF10A, TNFRSF10D, TNFRSF13B [TNFRSF13C]), and a suppressor of cytokine 
signaling (SOCS1); chemokines [CCL1, CCL5, CCL19]; proteins involved in collagen 
formation and fibroblast growth factor (COL9A3, COL13A, COL13A1, FGF21); 
receptor molecules involved in metabolism (IRS1, PEX3, PEX13, PPARG, PPARGC1B 
[PPARD, LRP1B, LRP2, LRP6, LRP8, VLDLR]); adhesion molecule (ICAM4); and 
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proteases or molecules associated with bone metabolism (BAMBI, CASP6, MMP21 
[MMP3, MMP10, MMP13, MMP16, OSTF1]). 
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TABLE 2 
 
Table 2: Comparison of statistically significant differential miRNA expression 
according to periodontal status and BMI. 
 
PERIODONTAL STATUS 
Healthy Periodontium compared to 
Periodontitis 
BMI STATUS 
Non-obese compared to  
Obese 
Periodontitis 
(Non-obese) 
Periodontitis 
Obese 
Obese 
(Healthy Periodontium) 
miR-30e 
miR-106b 
 
miR-106b 
**
 
miR-130a 
miR-142-3p 
**
 
miR-15a 
miR-30d 
miR-22 
miR-103 
miR-185 
miR-210 
miR-30e 
miR-18a 
**
 P <0.01 
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DISCUSSION 
 It is well established that obesity leads to numerous morbidities such as 
cardiovascular and cerebrovascular disease and is associated with increased mortality 
from cardiovascular events and malignancies. Several miRNAs have also already been 
implicated with the pathogenesis of certain human diseases. As an impetus to discovering 
new therapeutic targets for adipogenesis, new discoveries have been made regarding 
certain miRNAs and their central role in adipocyte differentiation, metabolic functions 
and insulin resistance (Heneghan et al. 2009). Conversely, few reports indicate the role of 
miRNAs in periodontal disease pathogenesis. A single experimental polymicrobial 
periodontitis model in mice showed increased miR-146a expression (Nahid et al. 2011) 
but no further human reports exist. Therefore, the effect of miRNA transcriptional 
repression or mRNA cleavage on periodontal pathogenesis, especially in the presence of 
obesity, is largely unknown. 
 The miRNA predicted targets observed in this study focused primarily on key 
aspects of periodontal pathogenesis and obesity: inflammatory cytokines, immune 
regulation, bone and glucose metabolism. We found an up-regulation of miR-30e in the 
obese (and periodontally healthy) patient group. Klöting et al. (2009) is the only report to 
have found increased expression of miR-30e in subcutaneous adipose tissue and 
suggested its potential involvement in the association between adipose tissue dysfunction 
and the development of obesity related disorders like non-insulin dependent diabetes 
mellitus (NIDDM). Conversely, up-regulation of miR-30e was also observed in the non-
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obese and periodontally diseased subset of patients. To date, no published studies have 
described an association between miR-30e and periodontal disease or inflammatory 
modulation. Nevertheless, the assumption then may be that the similarity between the 
obese and periodontally healthy subset and the non-obese and periodontally diseased 
subset is an underlying inflammatory process which may be related to miR-30e up-
regulation. While none of the study participants had diabetes, a predicted target for miR-
30e was IRS1, an insulin receptor substrate. Interestingly, expression of miR-30e was not 
significant in the subset of patients with both an obese status and periodontal disease and 
expression of nine other miRNAs was more impressive. 
Up-regulation of miR-103 was observed in participants with periodontal disease 
and an obese BMI. An up-regulation of miR-103 (Xie et al. 2009) and miR-143 (Esau et 
al. 2004; Kajimoto et al. 2006) was observed during adipogenesis. Xie et al. (2009) were 
the first to provide cell culture and animal model evidence that miR-103 has a critical 
role in adipose biology, whereby presence of miR-103 in pre-adipocytes accelerated 
adipogenesis. Much of the predicted targets found for miR-103 were only validated in 2 
out of 3 miRNA databases. Represented in this group were members of complement-
related genes (C1QB, C1QL3), growth factors (FGF12, FGFR2, FIGF), interferon 
(IFNK), interleukins (IL1F8, IL20) and insulin-like peptide INSL5 (Appendix C). While 
miR-143 expression was not found in this study, it is significantly associated with 
elevated body weight and mesenteric fat weight in mice fed a high-fat diet. Adipocyte 
differentiation markers like PPARγ, aP2 and plasma leptin levels were intimately 
correlated with miR-143 expression levels (Takanabe et al. 2008). 
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Similarly, an interesting association between an inflammatory disease and BMI 
was found by Iliopoulos and colleagues (2008). Human osteoarthritic cartilage was 
obtained and compared it with normal cartilage. Among the most important differences, 
specific miRNAs (miR-22, miR-103) and proteins (PPARA, BMP7, IL1B) were highly 
correlated with Body Mass Index (BMI). Furthermore, miR-22 was found to regulate 
PPARA and BMP7 expression while inhibition of miR-22 causes up-regulation of 
PPARA and BMP7, blocked the inflammatory process through inhibition of IL1B and 
promoted repair in osteoarthritic chondrocytes (Iliopoulos et al. 2008). Our study also 
found a significant up-regulation in miR-22 expression in the obese and periodontally 
diseased group compared to healthy/non-obese controls. In silico analysis did not find 
similar predicted targets as demonstrated in the aforementioned study. However, 
computationally-derived mRNA targets still related to metabolic pathways (APOA5, 
IGFBP4) and inflammation (IL13RA1, IL1F9, IL27RA, IL31, IRF5, TNFRSF10D, 
TNFRSF13B) (Appendix C). 
No unique miRNAs were found in the periodontally diseased (and non-obese) 
study subset. Instead, miR-30e expression was shared as previously mentioned with the 
periodontally healthy but obese group. In addition, expression of miR-106b was shared 
with the periodontally diseased and obese group with the most impressive fold regulation 
(6.4-fold) and highest level of statistical significance. Much of the literature implicating 
miR-106b in disease pathogenesis is related to carcinogenesis and cell cycle regulation. 
For the first time, miR-106b predicted targets in this study suggest that it is related to 
inflammation and bone metabolism pathways. In particular, prostaglandin E2 receptor 
(PTGER3) and tumor necrosis factor superfamily members (TNFSF14, TNFRSF10A) 
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were potential targets (Appendix C). PGE2 and TNF are established markers of gingival 
inflammation within gingival crevicular fluid (Adrianakaja et el. 2009). Confirmation of 
these in silico findings could be performed by performing a functional assay using a 
luciferase reporter construct to assess, for instance, alterations in PGE2 or TNF 
expression. Furthermore, in vitro over-expression and knockdown studies can be initiated 
and finally knockout mice may be generated to validate these findings. 
Other important miRNAs (miR-15a, -18a, -30d, -130a, -142-3p, -185, -210) were 
expressed uniquely in the periodontally disease and obese subset. Similarly, the predicted 
targets related to immune regulation, collagen metabolism and insulin and cholesterol 
metabolism (Appendix C). The impressive number of miRNAs up-regulated in this group 
potentially suggests an additive effect of inflammatory burden of these two chronic 
diseases. A small study population was used for this proof-of-concept study but larger 
cohorts will be necessary to further validate these findings. In addition, in silico findings 
must be validated using a luciferase reporter transfection model, in vitro over-expression 
and knockdown studies may be initiated, followed by generation of knockout mice. 
In conclusion, 11 miRNAs were differentially expressed in subsets of patients 
with either healthy or diseased gingiva or either non-obese or obese BMI. Nine of these 
miRNA were expressed by participants with both periodontal disease and an obese BMI. 
Several predicted targets were identified for these miRNA, many of which are implicated 
in immune and inflammatory pathways and metabolic processes (glucose and lipid-
related). The miRNAs identified in this study may play a crucial role in the pathogenesis 
of periodontal infection modified by obesity as well as provide a basis for further 
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investigations regarding the effect of obesity on periodontal pathogenesis. In doing so, 
these miRNA may represent novel therapeutic targets.  
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APPENDIX A 
SUPPLEMENTARY MATERIALS AND METHODS 
 
Institutional Review Board, University of North Carolina at Chapel Hill. 
IRB Study Number 07-0749 
 
Clinical Study Design 
This was a cross-sectional case-control study in which clinical parameters and 
biological samples were collected from both obese and non-obese subjects that presented 
with a healthy periodontium or chronic periodontitis. The study was conducted in a single 
masked or blinded manner such that all laboratory assessments were performed without 
knowledge of the subjects’ BMI or periodontal status. 
 
Human Subjects 
A total of 24 subjects were recruited from the GO Health Center and the Graduate 
Periodontology clinic at the University of North Carolina - School of Dentistry.  Height 
and weight measurements were collected on all recruited subjects in order to assess Body 
Mass Index (BMI). Participants were divided into two groups based on BMI. Group one 
consisted of 12 non-obese subjects (BMI <30 kg/m
2
) and was further divided into two 
subsets: six patients with healthy periodontium and 6 patients with chronic periodontitis.  
Group 2 consisted of 12 obese subjects (BMI >30 kg/m
2
) and was similarly divided into 
two subsets: six patients with healthy periodontium and 6 patients with chronic 
periodontitis. In both groups, patients had a tissue sample collected (either during crown 
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lengthening, extraction, or periodontal procedure appointment). The tissue was 
subsequently used for evaluation of miRNA expression profile. Additionally, a 
comprehensive periodontal examination was performed at the time of biopsy collection 
along with gingival crevicular fluid and plaque sample collection. Smoking and diabetes 
information was collected and examined post-hoc for evidence of significant effect 
modification. 
The inclusion criteria for study participation included: (1) male or female subjects 
between the ages of 18-65 years (inclusive) and in good general health, (2) must have 
been able and willing to follow study procedures and instructions, (3) must have been 
able to read, understand and sign an informed consent form, (4) must have presented with 
at least 20 teeth in the functional dentition, excluding third molars. Of the total 24 
recruited participants, half must have presented with chronic periodontitis as determined 
by two calibrated examiners during the periodontal examination. Such subjects exhibited 
periodontal pocketing (>5 mm and Bleeding on Probing) and severe alveolar bone loss. 
Control subjects must have presented with periodontal health as determined by two 
calibrated examiners during the periodontal examination. Such subjects exhibited no 
evidence of periodontal pocketing (PDs ≤4mm), no bleeding on probing at the site of the 
biopsy or radiographic bone loss.  
Patients were ineligible based on these exclusion criteria: (1) individuals who had 
a chronic disease and presented with oral manifestations, (2) individuals who exhibited 
gross oral pathology, (3) treatment with antibiotics for any medical or dental condition 
within 1 month prior to the screening examination, (4) chronic treatment (i.e., two weeks 
or more) with any medication known to affect periodontal status (e.g., phenytoin, calcium 
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antagonists, cyclosporin, coumadin, non-steroidal anti-inflammatory drugs, aspirin 
>81mg) within one month of the screening examination, (5) ongoing medications 
initiated less than three months prior to enrollment, (6) subjects with clinically significant 
organ disease including impaired renal function, or any bleeding disorder, (7) subjects 
with active infectious diseases such as hepatitis, HIV or tuberculosis, (8) severe 
unrestored caries, or any condition that is likely to require antibiotic treatment over the 
trial, including the need for prophylactic antibiotics.  
 
Clinical Study Methods 
All study participants had the following procedures performed on them at a single 
visit with the restriction that all biological specimens were also collected on the same 
day.  
 Study personnel obtained medical history and demographics related to the patient 
 Patient height and weight were recorded on site 
 Patient vital signs (blood pressure and pulse) were recorded 
 Two calibrated dental examiner performed oral and periodontal screening 
examinations 
 The dental examiner collected 16 gingival crevicular fluid samples from the 
interproximal surfaces of the molars and premolars for future inflammatory 
mediator analyses making sure to include the biopsy site 
 The dental examiner collected subgingival plaque sample(s) from the site(s) of the 
biopsy(ies) for future microbial DNA analyses 
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 The dental examiner scored all teeth for probing depth, percent bleeding on 
probing and clinical attachment level  
 For healthy subjects, 1 gingival biopsy sample (gingival epithelium and 
connective tissue) per subject was collected at the time of a scheduled crown 
extension procedure, extraction, or voluntarily in the Go Health Clinic.  The 
sample was obtained with a 4 mm punch biopsy blade or scalpel blade. This 
biopsy site selected within the subject was the site of the crown extension 
procedure, or at the interproximal papillae with a probing depth ≤4 mm. 
 For subjects with chronic periodontitis, two gingival biopsy samples were 
obtained at the time of a scheduled periodontal flap procedure. Both samples were 
obtained with a 4 mm punch or scalpel blade. One sample was obtained from a 
severe inflamed periodontitis site (probing depth >5mm) and the other was 
obtained from an adjacent, minimally inflamed disease-free site (probing depth <4 
mm). The latter sample was stored for future studies and not analyzed in this 
study. 
 
Clinical Periodontal Assessments   
 Clinical examiners were calibrated prior to commencement of the study for 
training of study procedures. 
Clinical parameters assessed in the periodontal examination included probing 
depth, bleeding on probing, and clinical attachment level. Clinical parameters were 
measured using a manual University of North Carolina (UNC-15) periodontal probe. For 
periodontitis and periodontally healthy subjects, these parameters were measured at six 
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periodontal sites per tooth (i.e., mesiobuccal, buccal, distobuccal, mesiolingual, lingual, 
and distolingual) and at all teeth (including third molars). Probing depth (PD) was 
defined as the linear distance from the gingival margin to base of the pocket. If a PD 
reading fell between two millimeter readings, the rule was to round down and the lower 
of the two readings was recorded. Presence or absence of bleeding to manual probing was 
recorded as a dichotomous variable where 0 indicated that there was no bleeding within 
10 seconds after probing and 1 indicated that bleeding was produced within 10 seconds 
after probing. The clinical attachment level (CAL) was defined as the linear distance 
from the cemento-enamel junction to base of the pocket. If a CAL reading fell between 
two millimeter readings, the rule was to round down and the lower of the two readings 
was recorded.   
 
General Assessments 
Blood pressure was recorded for all patients using an automated blood pressure 
machine. BMI was collected for each participant based on recorded height and weight 
measurements taken at the time of examination. BMI categories include: underweight 
<18.5 kg/m
2
, normal weight 18.5-24.9 kg/m
2
, overweight 25-29.9 kg/m
2
, obesity >30 
kg/m
2
. For the purposes of this study, participants were initially either categorized as 
non-obese (<30 kg/m
2
) or obese (>30 kg/m
2
). 
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APPENDIX B 
ARRAY LAYOUT  
 
RT
2
 microRNA PCR Array Human miFinder (MAH-001A)  
(SABiosciences, Frederick, MD) 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A miR-142-5p miR-16 miR-142-3p miR-21 miR-15a miR-29b let-7a miR-126 miR-143 let-7b miR-27a let-7f 
B miR-9 miR-26a miR-24 miR-30e miR-181a miR-29a miR-124 miR-144 miR-30d miR-19b miR-22 miR-122 
C miR-150 miR-32 miR-155 miR-140-5p miR-125b miR-141 miR-92a miR-424 miR-191 miR-17 miR-130a miR-20a 
D miR-27b miR-26b miR-146a miR-200c miR-99a miR-19a miR-23a miR-30a let-7i miR-93 let-7c miR-106b 
E miR-101 let-7g miR-425 miR-15b miR-28-5p miR-18a miR-25 miR-23b miR-302a miR-186 miR-29c miR-7 
F let-7d miR-30c miR-181b miR-223 miR-320a miR-374a let-7e miR-151-5p miR-374b miR-196b miR-140-3p miR-100 
G miR-103 miR-96 miR-302b miR-194 miR-125a-5p miR-423-5p miR-376c miR-195 miR-222 miR-28-3p miR-128 miR-302c 
H miR-423-3p miR-185 miR-30b miR-210 SNORD48 SNORD47 SNORD44 U6 miRTC miRTC PPC PPC 
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APPENDIX C 
TARGET GENES AND GO TERMS 
 
Identified in 3 out of 4 databases 
miRNA Gene Description GO Term 
miR-22 APOA5 Apolipoprotein A-V precursor 
(Apolipoprotein A5) (ApoAV) 
(ApoA-V) (Regeneration-associated 
protein 3).  
cholesterol 
homeostasis 
miR-106b BAMBI BMP and activin membrane-bound 
inhibitor homolog precursor 
(Putative transmembrane protein 
NMA) (Non-metastatic gene A 
protein). 
transforming 
growth factor 
beta receptor 
signaling 
pathway 
miR-15a BMX Cytoplasmic tyrosine-protein kinase 
BMX (EC 2.7.10.2) (Bone marrow 
tyrosine kinase gene in chromosome 
X protein) (Epithelial and 
endothelial tyrosine kinase) (ETK) 
(NTK38). 
apoptosis 
miR-106b CASP6 Caspase-6 precursor (EC 3.4.22.59) 
(CASP-6) (Apoptotic protease Mch-
2) 
apoptosis 
 
miR-106b CCL1 Small inducible cytokine A1 
precursor (CCL1) (T lymphocyte-
secreted protein I-309) 
chemotaxis 
miR-106b CD68 Macrosialin precursor (GP110) 
(CD68 antigen) 
 
miR-106b CFLAR CASP8 and FADD-like apoptosis 
regulator precursor (Cellular FLICE-
like inhibitory protein) (c-FLIP) 
(Caspase-eight-related protein) 
(Casper) (Caspase-like apoptosis 
regulatory protein) (CLARP) 
(MACH-related inducer of toxicity) 
(MRIT) (Caspase homolog) 
apoptosis 
miR-30d 
miR-130a 
CHST1 Carbohydrate sulfotransferase 1 (EC 
2.8.2.21) (Keratan sulfate Gal-6 
sulfotransferase) (KSST) 
(KSGal6ST) (KS6ST) (Galactose/N- 
acetylglucosamine/N-
acetylglucosamine 6-O-
sulfotransferase 1) (GST-1).  
inflammatory 
response 
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miR-30d CHST2 Carbohydrate sulfotransferase 2 (EC 
2.8.2.-) (N-acetylglucosamine 6-O- 
sulfotransferase 1) (GlcNAc6ST-1) 
(Gn6ST) (Galactose/N- 
acetylglucosamine/N-
acetylglucosamine 6-O-
sulfotransferase 2) (GST-2). 
inflammatory 
response 
miR-30e COL9A3 Collagen alpha-3(IX) chain 
precursor.  
axon guidance 
miR-30e COL13A Collagen alpha-1(XIII) chain 
(COLXIIIA1). 
cell-cell 
adhesion 
miR-30d COL13A1 Collagen alpha-1(XIII) chain 
(COLXIIIA1). 
cell-cell 
adhesion 
miR-22 CSF1R Macrophage colony-stimulating 
factor 1 receptor precursor (EC 
2.7.10.1) (CSF-1-R) (Fms proto-
oncogene) (c-fms) (CD115 antigen). 
signal 
transduction 
miR-30e CTHRC1 Collagen triple helix repeat-
containing protein 1 precursor 
(NMTC1 protein).  
cell migration 
miR-30e FCER1G High affinity immunoglobulin 
epsilon receptor gamma-subunit 
precursor (FceRI gamma) (IgE Fc 
receptor gamma-subunit) (Fc-epsilon 
RI-gamma).  
leukocyte 
migration 
 
miR-15a FCRL2 Fc receptor-like protein 2 precursor 
(FcR-like protein 2) (FcRL2) (Fc 
receptor homolog 2) (FcRH2) (SH2 
domain-containing phosphatase 
anchor protein 1) (Immunoglobulin 
receptor translocation-associated 4 
protein). 
cell-cell 
signaling 
miR-30e FCN1 
 
Ficolin-1 precursor (Ficolin-A) 
(Ficolin-alpha) (M-ficolin) 
(Collagen/fibrinogen domain-
containing protein 1).  
opsonization 
miR-30e FGF21 Fibroblast growth factor 21 
precursor (FGF-21).  
cell-cell 
signaling 
miR-106b FGL2 Fibroleukin precursor (Fibrinogen-
like protein 2) (pT49) 
signal 
transduction 
miR-106b FNDC3A Fibronectin type-III domain-
containing protein 3a. 
cell-cell 
adhesion 
miR-18a FRS2 Fibroblast growth factor receptor 
substrate 2 (FGFR substrate 2) 
(Suc1-associated neurotrophic factor 
target 1) (SNT-1) (FGFR-signaling 
fibroblast 
growth factor 
receptor 
signaling 
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adaptor SNT). pathway 
miR-130a GADD45A Growth arrest and DNA-damage-
inducible protein GADD45 alpha 
(DNA- damage-inducible transcript 
1) (DDIT1). 
apoptosis 
miR-142-
3p 
HGS Hepatocyte growth factor-regulated 
tyrosine kinase substrate (Protein 
pp110) 
signal 
transduction 
miR-106b ICAM4 Intercellular adhesion molecule 4 
precursor (ICAM-4) (Landsteiner- 
Wiener blood group glycoprotein) 
(LW blood group protein) (CD242 
antigen) 
cell adhesion 
miR-30e IFNA16 Interferon alpha-16 precursor 
(Interferon alpha-WA).  
defense 
response 
miR-30e IFNA21 Interferon alpha-21 precursor 
(Interferon alpha-F) (LeIF F). 
defense 
response 
miR-30e IFNAR2 Interferon-alpha/beta receptor beta 
chain precursor (IFN-alpha-REC) 
(Type I interferon receptor) (IFN-R) 
(Interferon alpha/beta receptor 2).  
cytokine-
mediated 
signaling 
pathway 
miR-22 IGFBP4 Insulin-like growth factor-binding 
protein 4 precursor (IGFBP-4) (IBP- 
4) (IGF-binding protein 4).  
inflammatory 
response 
miR-30e IL1A Interleukin-1 alpha precursor (IL-1 
alpha) (Hematopoietin-1). 
inflammatory 
response 
miR-30d IL1AQ Interleukin-1 alpha precursor (IL-1 
alpha) (Hematopoietin-1).  
N/A 
miR-106b ILDR1 immunoglobulin-like domain 
containing receptor 1 
N/A 
miR-22 IL13RA1 Interleukin-13 receptor alpha-1 chain 
precursor (IL-13R-alpha-1) (IL- 
13RA-1) (CD213a1 antigen).  
cell surface 
receptor linked 
signaling 
pathway 
miR-22 IL1F9 Interleukin-1 family member 9 (IL-
1F9) (Interleukin-1 homolog 1) (IL- 
1H1) (Interleukin-1 epsilon) (IL-1 
epsilon) (IL-1-related protein 2) (IL-
1RP2).  
cell-cell 
signaling 
miR-22 IL27RA Interleukin-27 receptor subunit alpha 
precursor (IL-27R-alpha) (WSX-1) 
(Type I T-cell cytokine receptor) 
(TCCR) (Protein CRL1).  
immune 
response 
miR-22 IL31 Interleukin-31 precursor (IL-31).  N/A 
miR-18a IRF2 Interferon regulatory factor 2 (IRF-
2).  
interfereon-
gamma-
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mediated 
signaling 
pathway 
miR-22 IRF5 Interferon regulatory factor 5 (IRF-
5).  
 
interfereon-
gamma-
mediated 
signaling 
pathway 
miR-30d 
miR-30e 
IRS1 Insulin receptor substrate 1 (IRS-1). glucose 
homesostasis 
miR-106b ITFG1 T-cell immunomodulatory protein 
precursor (Protein TIP) (Integrin 
alpha FG-GAP repeat-containing 
protein 1) 
integral to 
membrane 
miR-106b LIAS Lipoic acid synthetase, 
mitochondrial precursor (Lip-syn) 
(Lipoate synthase).  
inflammatory 
response 
miR-106b LILRB1 Leukocyte immunoglobulin-like 
receptor subfamily B member 1 
precursor (Leukocyte 
immunoglobulin-like receptor 1) 
(LIR-1) (Immunoglobulin- like 
transcript 2) (ILT-2) 
(Monocyte/macrophage 
immunoglobulin-like receptor 7) 
(MIR-7) (CD85j antigen).  
regulation of 
immune 
response 
miR-142-
3p 
LRP1B Low-density lipoprotein receptor-
related protein 1B precursor (Low- 
density lipoprotein receptor-related 
protein-deleted in tumor) 
protein 
transport 
miR-15a LRP6 Low-density lipoprotein receptor-
related protein 6 precursor. 
bone 
remodeling 
miR-130a LRP8 Low-density lipoprotein receptor-
related protein 8 precursor 
(Apolipoprotein E receptor 2). 
cytokine-
mediated 
signaling 
pathway 
miR-106b MAP3K11 Mitogen-activated protein kinase 
kinase kinase 11 (EC 2.7.11.25) 
(Mixed lineage kinase 3) (Src-
homology 3 domain-containing 
proline- rich kinase). 
cell death 
 
miR-106b MAPK9 Mitogen-activated protein kinase 9 
(EC 2.7.11.24) (Stress-activated 
protein kinase JNK2) (c-Jun N-
terminal kinase 2) (JNK-55). 
Toll signaling 
pathway 
miR-130a MET Hepatocyte growth factor receptor signal 
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precursor (EC 2.7.10.1) (HGF 
receptor) (Scatter factor receptor) 
(SF receptor) (HGF/SF receptor) 
(Met proto-oncogene tyrosine 
kinase) (c-Met). 
transduction 
miR-30e MMD Monocyte to macrophage 
differentiation protein (Progestin and 
adipoQ receptor family member XI).  
cytolysis 
miR-30e MMP21 Matrix metalloproteinase-21 
precursor (EC 3.4.24.-) (MMP-21). 
proteolysis 
miR-15a NFATC3 Nuclear factor of activated T-cells, 
cytoplasmic 3 (NF-ATc3) (NFATc3) 
(T cell transcription factor NFAT4) 
(NF-AT4) (NFATx) 
regulation of 
transcription 
miR-185 NFATC3 Nuclear factor of activated T-cells, 
cytoplasmic 3 (NF-ATc3) (NFATc3) 
(T cell transcription factor NFAT4) 
(NF-AT4) (NFATx) 
regulation of 
transcription 
miR-30d NFIB 
 
Nuclear factor 1 B-type (Nuclear 
factor 1/B) (NF1-B) (NFI-B) (NF-
I/B) (CCAAT-box-binding 
transcription factor) (CTF) 
(TGGCA-binding protein). 
regulation of 
transcription, 
DNA-
dependent 
miR-106b PBK T-lymphokine-activated killer cell-
originated protein kinase (EC 
2.7.12.2) (T-LAK cell-originated 
protein kinase) (PDZ-binding 
kinase) (Spermatogenesis-related 
protein kinase) (SPK) (MAPKK-like 
protein kinase) (Nori-3). 
protein 
phosphorylation 
miR-30e PEX3 Peroxisomal biogenesis factor 3 
(Peroxin-3) (Peroxisomal assembly 
protein PEX3).  
protein import 
into peroxisome 
membrane 
miR-15a PEX13 Peroxisomal membrane protein 
PEX13 (Peroxin-13). 
fatty-acid alpha-
oxidation 
miR-142-
3p 
PGM1 Phosphoglucomutase-1 (EC 5.4.2.2) 
(Glucose phosphomutase 1) (PGM 
1). 
carbohydrate 
metabolic 
process 
miR-130a PPARG Peroxisome proliferator-activated 
receptor gamma (PPAR-gamma). 
lipid 
homeostasis 
miR-30d PPARGC1B Peroxisome proliferator-activated 
receptor gamma coactivator 1-beta 
(PPAR gamma coactivator-1beta) 
(PGC-1-related estrogen receptor 
alpha coactivator) (PPARGC-1-beta) 
(PGC-1-beta). 
regulation of 
transcription 
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miR-106b PTGER3 Prostaglandin E2 receptor, EP3 
subtype (Prostanoid EP3 receptor) 
(PGE receptor, EP3 subtype) (PGE2-
R) 
signal 
transduction 
miR-30d 
miR-30e 
SOCS1 Suppressor of cytokine signaling 1 
(SOCS-1) (JAK-binding protein) 
(JAB) (STAT-induced STAT 
inhibitor 1) (SSI-1) (Tec-interacting 
protein 3) (TIP-3). 
cytokine-
mediated 
signaling 
pathway 
miR-130a STARD13 StAR-related lipid transfer protein 
13 (StARD13) (START domain- 
containing protein 13) (46H23.2) 
(Deleted in liver cancer protein 2) 
(Rho GTPase-activating protein).  
signal 
transduction 
miR-18a TNFAIP3 Tumor necrosis factor, alpha-
induced protein 3 (Putative DNA-
binding protein A20) (Zinc finger 
protein A20).  
negative 
regulation of 
inflammatory 
response OR 
signal 
transduction 
miR-130a TNF Tumor necrosis factor precursor 
(TNF-alpha) (Tumor necrosis factor 
ligand superfamily member 2) 
(TNF-a)  
chronic 
inflammatory 
response to 
antigenic 
stimulus 
miR-106b TNFRSF10A Tumor necrosis factor receptor 
superfamily member 10A precursor 
(Death receptor 4) (TNF-related 
apoptosis-inducing ligand receptor 
1) (TRAIL receptor 1) (TRAIL-R1) 
(CD261 antigen). 
activation of 
NK-kappaB-
inducing kinase 
activity 
miR-22 TNFRSF10D Tumor necrosis factor receptor 
superfamily member 10D precursor 
(Decoy receptor 2) (DcR2) (TNF-
related apoptosis-inducing ligand 
receptor 4) (TRAIL receptor 4) 
(TRAIL-R4) (TRAIL receptor with a 
truncated death domain) (CD264 
antigen).  
signal 
transduction 
miR-22 TNFRSF13B Tumor necrosis factor receptor 
superfamily member 13B 
(Transmembrane activator and 
CAML interactor) (CD267 antigen).  
B cell 
homeostasis 
miR-30e TNFSF8 Tumor necrosis factor ligand 
superfamily member 8 (CD30 
ligand) (CD30- L) (CD153 antigen).  
signal 
transduction 
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miR-106b TNFSF14 Tumor necrosis factor ligand 
superfamily member 14 
(Herpesvirus entry mediator-ligand) 
(HVEM-L) (CD258 antigen) 
[Contains: Tumor necrosis factor 
ligand superfamily member 14, 
membrane form; Tumor necrosis 
factor ligand superfamily member 
14, soluble form]  
immune 
response 
miR-106b VLDLR Very low-density lipoprotein 
receptor precursor (VLDL receptor) 
(VLDL- R). 
cholesterol 
metabolic 
process 
 
Identified in 2 out of 3 databases 
miRNA Gene Description GO Term 
miR-30d ADAM22 ADAM 22 precursor (A disintegrin 
and metalloproteinase domain 22) 
(Metalloproteinase-like, disintegrin-
like, and cysteine-rich protein 2) 
(Metalloproteinase-disintegrin 
ADAM22-3). 
proteolysis 
miR-130a ADAM23 ADAM 23 precursor (A disintegrin 
and metalloproteinase domain 23) 
(Metalloproteinase-like, disintegrin-
like, and cysteine-rich protein 3) 
(MDC-3). 
proteolysis 
miR-30d ADAMTS6 ADAMTS-6 precursor (EC 3.4.24.-) 
(A disintegrin and metalloproteinase 
with thrombospondin motifs 6) 
(ADAM-TS 6) (ADAM-TS6). 
proteolysis 
miR-185 AGER Advanced glycosylation end 
product-specific receptor precursor 
(Receptor for advanced 
glycosylation end products). 
inflammatory 
response 
miR-130a CAPRIN2 C1q domain containing 1 isoform 2 negative 
regulation of 
translation 
miR-103 C1QB Complement C1q subcomponent 
subunit B precursor. 
complement 
activation 
miR-30d C1QL1 C1q-related factor precursor 
(Complement component 1 Q 
subcomponent- like 1). 
locomotory 
behavior 
miR-103 C1QL3 Complement C1q-like protein 3 
precursor. 
N/A 
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miR-106b CCL5 Small inducible cytokine A5 
precursor (CCL5) (T-cell-specific 
RANTES protein) (SIS-delta) (T 
cell-specific protein P228) (TCP228) 
cellular defense 
response 
miR-30d CCL19 Small inducible cytokine A19 
precursor (CCL19) (Macrophage 
inflammatory protein 3 beta) (MIP-
3-beta) (EBI1-ligand chemokine) 
(ELC) (Beta chemokine exodus-3) 
(CK beta-11). 
inflammatory 
response 
miR-106b CCS Copper chaperone for superoxide 
dismutase (Superoxide dismutase 
copper chaperone). 
removal of 
superoxide 
radicals 
miR-106b CD1B T-cell surface glycoprotein CD1b 
precursor (CD1b antigen). 
immune 
response 
miR-210 CD22 B-cell receptor CD22 precursor 
(Sialic acid-binding Ig-like lectin 2) 
(Siglec-2) (Leu-14) (B-lymphocyte 
cell adhesion molecule) (BL-CAM). 
cell adhesion 
miR-103 CD28 T-cell-specific surface glycoprotein 
CD28 precursor (TP44). 
humoral 
immune 
response 
miR-30d CD99 CD99 antigen precursor (T-cell 
surface glycoprotein E2) (E2 
antigen) (Protein MIC2) (12E7). 
cell adhesion 
miR-103 CHST11 Carbohydrate sulfotransferase 11 
(EC 2.8.2.5) (Chondroitin 4-O- 
sulfotransferase 1) (Chondroitin 4-
sulfotransferase 1) (C4ST) (C4ST-1) 
(C4S-1). 
carbohydrate 
biosynthetic 
process 
miR-30d COL9A3 Collagen alpha-3(IX) chain 
precursor. 
axon guidance 
miR-210 CR1 Complement receptor type 1 
precursor (C3b/C4b receptor) (CD35 
antigen). 
innate immune 
response 
miR-106b CSF2RA Granulocyte-macrophage colony-
stimulating factor receptor alpha 
chain precursor (GM-CSF-R-alpha) 
(GMR) (CD116 antigen) (CDw116). 
N/A 
miR-185 CSF2RB Cytokine receptor common beta 
chain precursor (GM-CSF/IL-3/IL-5 
receptor common beta-chain) 
(CD131 antigen) (CDw131). 
signal 
transduction 
miR-142-
3p 
CXADR Coxsackievirus and adenovirus 
receptor precursor (Coxsackievirus 
B- adenovirus receptor) (hCAR) 
leukocyte 
migration 
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(CVB3-binding protein) 
(HCVADR). 
miR-106b DIS3L DIS3 mitotic control homolog (S. 
cerevisiae)-like 
N/A 
miR-185 EBI3 Interleukin-27 beta chain precursor 
(IL-27B) (Epstein-Barr virus- 
induced gene 3 protein) (EBV-
induced gene 3 protein). 
cytokine-
mediated 
signaling 
pathway 
miR-130a EDG1 Sphingosine 1-phosphate receptor 
Edg-1 (Sphingosine 1-phosphate 
receptor 1) (S1P1). 
positive 
regulation of 
positive 
chemotaxis 
miR-130a F3 Tissue factor precursor (TF) 
(Coagulation factor III) 
(Thromboplastin) (CD142 antigen). 
positive 
regulation of 
positive 
chemotaxis 
miR-103 FAT4 FAT tumor suppressor homolog 4 cell adhesion 
miR-30d FCER1G High affinity immunoglobulin 
epsilon receptor gamma-subunit 
precursor (FceRI gamma) (IgE Fc 
receptor gamma-subunit) (Fc-epsilon 
RI-gamma). 
leukocyte 
migration 
 
miR-185 FCRL3 Fc receptor-like 3 precursor N/A 
miR-22 FFAR3 Free fatty acid receptor 3 (G-protein 
coupled receptor 41). 
protein coupled 
receptor protein 
signaling 
pathway 
miR-103 FGF12 Fibroblast growth factor 12 (FGF-
12) (Fibroblast growth factor 
homologous factor 1) (FHF-1) 
(Myocyte-activating factor). 
cell-cell 
signaling 
miR-103 FGFR2 Fibroblast growth factor receptor 2 
precursor (EC 2.7.10.1) (FGFR-2) 
(Keratinocyte growth factor receptor 
2) (CD332 antigen). 
bone 
morphogenesis 
miR-142-
3p 
FLT1 Vascular endothelial growth factor 
receptor 1 precursor (EC 2.7.10.1) 
(VEGFR-1) (Vascular permeability 
factor receptor) (Tyrosine-protein 
kinase receptor FLT) (Flt-1) 
(Tyrosine-protein kinase FRT) (Fms-
like tyrosine kinase 1). 
intracellular 
receptor 
mediated 
signaling 
pathway 
miR-103 FIGF Vascular endothelial growth factor D 
precursor (VEGF-D) (c-fos-induced 
growth factor) (FIGF). 
induction of 
positive 
chemotaxis 
miR-30d GLCCI1 Glucocorticoid-induced transcript 1 N/A 
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protein. 
miR-15a GLS2 Glutaminase liver isoform, 
mitochondrial precursor (EC 3.5.1.2) 
(GLS) (L-glutamine 
amidohydrolase) (L-glutaminase). 
glutamine 
metabolic 
process 
miR-130a HLA-DOA HLA class II histocompatibility 
antigen, DO alpha chain precursor 
(MHC class II antigen DOA) (MHC 
DZ alpha) (MHC DN-alpha). 
immune 
response 
 
miR-142-
3p 
HSD17B4 Peroxisomal multifunctional enzyme 
type 2 (MFE-2) (D-bifunctional 
protein) (DBP) (17-beta-
hydroxysteroid dehydrogenase 4) 
(17-beta-HSD 4) (D-3-hydroxyacyl-
CoA dehydratase) (EC 4.2.1.107) (3-
alpha,7- alpha,12-alpha-trihydroxy-
5-beta-cholest-24-enoyl-CoA hy 
oxidation-
reduction 
process 
miR-106b IFIT3 Interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT-3) 
(IFIT-4) (Interferon-induced 60 kDa 
protein) (IFI-60K) (ISG-60) (CIG49) 
(Retinoic acid-induced gene G 
protein) (RIG-G). 
cytokine-
mediated 
signaling 
pathway 
miR-22 IKBKG NF-kappa-B essential modulator 
(NEMO) (NF-kappa-B essential 
modifier) (Inhibitor of nuclear factor 
kappa-B kinase subunit gamma) 
(IkB kinase subunit gamma) (I-
kappa-B kinase gamma) (IKK-
gamma) (IKKG) (IkB kinase-
associated protein 1) (IKKAP1) 
(FIP-3). 
immune 
response 
miR-18a IFNA1 Interferon alpha-1/13 precursor 
(Interferon alpha-D) (LeIF D). 
defense 
response 
miR-18a IFNA2 Interferon alpha-2 precursor 
(Interferon alpha-A) (LeIF A). 
inflammatory 
response 
miR-103 IFNK Interferon kappa precursor (IFN-
kappa). 
inflammatory 
response 
miR-103 IL1F8 Interleukin-1 family member 8 (IL-
1F8) (Interleukin-1 eta) (IL-1 eta) 
(FIL1 eta) (Interleukin-1 homolog 2) 
(IL-1H2). 
immune 
response 
miR-22 IL1RL1 Interleukin-1 receptor-like 1 
precursor (ST2 protein). 
immune 
response 
miR-130a IL15 Interleukin-15 precursor (IL-15). immune 
response 
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miR-18a IL9R Interleukin-9 receptor precursor (IL-
9R) (CD129 antigen). 
signal 
transduction 
miR-18a IL10RB Interleukin-10 receptor beta chain 
precursor (IL-10R-B) (IL-10R2) 
(Cytokine receptor family 2 member 
4) (Cytokine receptor class-II 
member 4) (CRF2-4) (CDw210b 
antigen). 
inflammatory 
response 
 
miR-18a IL17B Interleukin-17B precursor (IL-17B) 
(Cytokine-like protein Zcyto7) 
(Neuronal interleukin-17-related 
factor) (Interleukin-20) (IL-20). 
inflammatory 
response 
miR-103 IL20 Interleukin-20 precursor (IL-20) 
(Four alpha helix cytokine Zcyto10). 
regulation of 
inflammatory 
response 
miR-30d IL21R Interleukin-21 receptor precursor 
(IL-21R) (Novel interleukin 
receptor). 
natural killer 
cell activation 
miR-106b IL27RA Interleukin-27 receptor subunit alpha 
precursor (IL-27R-alpha) (WSX-1) 
(Type I T-cell cytokine receptor) 
(TCCR) (Protein CRL1). 
immune 
response 
miR-103 INSL5 Insulin-like peptide INSL5 precursor 
(Insulin-like peptide 5) [Contains: 
Insulin-like peptide INSL5 B chain; 
Insulin-like peptide INSL5 A chain]. 
biological 
process 
miR-15a INSR Insulin receptor precursor (EC 
2.7.10.1) (IR) (CD220 antigen) 
[Contains: Insulin receptor subunit 
alpha; Insulin receptor subunit beta]. 
positive 
regulation of 
glycolysis 
miR-30e 
miR-185 
LDLR Low-density lipoprotein receptor 
precursor (LDL receptor). 
cholesterol 
homeostasis 
miR-185 LDLRAD1 low density lipoprotein receptor A 
domain containing 1 
N/A 
miR-130a LIPI Lipase member I precursor (EC 
3.1.1.-) (Membrane-associated 
phosphatidic acid-selective 
phospholipase A1-beta) (mPA-PLA1 
beta) (LPD lipase). 
lipid catabolic  
process 
miR-130a LRP2 Low-density lipoprotein receptor-
related protein 2 precursor (Megalin) 
(Glycoprotein 330) (gp330). 
lipid metabolic 
process 
miR-18a LTBR Tumor necrosis factor receptor 
superfamily member 3 precursor 
(Lymphotoxin-beta receptor) 
(Tumor necrosis factor receptor 2-
signal 
transduction 
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related protein) (Tumor necrosis 
factor C receptor). 
miR-18a MASP1 Complement-activating component 
of Ra-reactive factor precursor (EC 
3.4.21.-) (Ra-reactive factor serine 
protease p100) (RaRF) (Mannan-
binding lectin serine protease 1) 
(Mannose-binding protein- 
associated serine protease) (MASP-
1) (Serine protease 5) 
proteolysis 
miR-130a MBD4 Methyl-CpG-binding domain protein 
4 (EC 3.2.2.-) (Methyl-CpG-binding 
protein MBD4) (Methyl-CpG-
binding endonuclease 1) (Mismatch-
specific DNA N-glycosylase). 
DNA damage 
response, signal 
transduction 
resulting in 
induction of 
apoptosis 
miR-18a MMP3 Stromelysin-1 precursor (EC 
3.4.24.17) (Matrix 
metalloproteinase-3) (MMP-3) 
(Transin-1) (SL-1). 
proteolysis 
miR-130a MMP10 Stromelysin-2 precursor (EC 
3.4.24.22) (Matrix 
metalloproteinase-10) (MMP-10) 
(Transin-2) (SL-2). 
proteolysis 
miR-130a MMP13 Collagenase 3 precursor (EC 3.4.24.-
) (Matrix metalloproteinase-13) 
(MMP-13). 
proteolysis 
miR-142-
3p 
MMP16 Matrix metalloproteinase-16 
precursor (EC 3.4.24.-) (MMP-16) 
(Membrane-type matrix 
metalloproteinase 3) (MT-MMP 3) 
(MTMMP3) (Membrane-type-3 
matrix metalloproteinase) (MT3-
MMP) (MT3MMP) (MMP- X2). 
proteolysis 
miR-18a NKIRAS1 NF-kappa-B inhibitor-interacting 
Ras-like protein 1 (I-kappa-B- 
interacting Ras-like protein 1) 
(Kappa B-Ras protein 1) (KappaB-
Ras1). 
I-kappaB 
kinase/ NF-
kappaB cascade 
miR-130a OSTF1 Osteoclast-stimulating factor 1. signal 
transduction 
miR-106b PLAUR Urokinase plasminogen activator 
surface receptor precursor (uPAR) 
(U- PAR) (Monocyte activation 
antigen Mo3) (CD87 antigen). 
chemotaxis 
miR-185 PGLYRP3 Peptidoglycan recognition protein I- defense 
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alpha precursor (Peptidoglycan 
recognition protein intermediate 
alpha) (PGRP-I-alpha) 
(PGLYRPIalpha) (Peptidoglycan 
recognition protein 3). 
response to 
Gram-positive 
bacterium 
miR-106b PPARD Peroxisome proliferator-activated 
receptor delta (PPAR-delta) (PPAR- 
beta) (Nuclear hormone receptor 1) 
(NUC1) (NUCI). 
adipose tissue 
development 
miR-30d TNFSF9 Tumor necrosis factor ligand 
superfamily member 9 (4-1BB 
ligand) (4- 1BBL). 
immune 
response 
miR-142-
3p 
TNFRSF13C Tumor necrosis factor receptor 
superfamily member 13C (B cell- 
activating factor receptor) (BAFF 
receptor) (BAFF-R) (BLyS receptor 
3) (CD268 antigen). 
regulation of 
immune 
response 
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